Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)

Annals of Hematology

Volumn 91, Issue 2, 2012, Pages 223-233

  Won, Young Woong ^a   Kwon, Jung Hye ^b   Lee, Soon Il ^c   Oh, Sung Yong ^d   Kim, Won Seog ^e   Kim, Seok Jin ^e   Won, Jong Ho ^f   Kim, Kyoung Ha ^f   Park, Seong Kyu ^g   Kim, Jin Seok ^h   Suh, Cheolwon ⁱ   Yoon, Dok Hyun ⁱ   Park, Joon Seong ^j   Kim, Min Kyoung ^k   Kim, Hawk ^l   Kang, Hye Jin ^m   Mun, Yeung Chul ⁿ   Kwak, Jae Yong ^o   Kim, Hyo Jung ^b   Eom, Hyeon Seok ^a  

^a National Cancer Center   (South Korea)

^b Hallym University   (South Korea)

^c Dankook University   (South Korea)

^d Dong A University   (South Korea)

^e Sungkyunkwan University   (South Korea)

^f Soonchunhyang University College of Medicine   (South Korea)

^g Soonchunhyang University   (South Korea)

^h Yonsei University College of Medicine   (South Korea)

ⁱ University of Ulsan College of Medicine   (South Korea)

^j Ajou University Medical CentSuwon   (South Korea)

^k Yeungnam University Hospital   (South Korea)

^l University of Ulsan College of Medicine   (South Korea)

^m Korea Cancer Center Hospital   (South Korea)

ⁿ Ewha Womans University   (South Korea)

^o Chonbuk National University Medical School   (South Korea)

more..

Author keywords

Hodgkin's lymphoma; Outcome; Prognosis; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BLEOMYCIN SULFATE; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOFOS; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INCIDENCE; CANCER STAGING; CAUSE OF DEATH; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; INFECTION; KOREA; LIBRARY SCIENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; STROKE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857372533     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1297-x     Document Type: Article

References (42)

1. Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H. SEER cancer statistics review, 1975-2007. National Cancer Institute, Bethesda
2. J Kuruvilla 2009 Standard therapy of advanced Hodgkin lymphoma Hematology Am Soc Hematol Educ Program 2009 497 506 10.1182/asheducation-2009.1.497
3. GP Canellos D Niedzwiecki 2002 Long-term follow-up of Hodgkin's disease trial N Engl J Med 346 1417 1418 11986425 10.1056/NEJM200205023461821 (Pubitemid 34754624)
4. DB Duggan GR Petroni JL Johnson JH Glick RI Fisher JM Connors GP Canellos BA Peterson 2003 Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial J Clin Oncol 21 607 614 12586796 10.1200/JCO.2003.12.086 1:CAS:528:DC%2BD2cXpsVGrtbg%3D (Pubitemid 46621893)
5. A Engert V Diehl J Franklin A Lohri B Dorken WD Ludwig P Koch M Hanel M Pfreundschuh M Wilhelm L Trumper WE Aulitzky M Bentz M Rummel O Sezer HK Muller-Hermelink D Hasenclever M Loffler 2009 Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study J Clin Oncol 27 4548 4554 19704068 10.1200/JCO.2008.19.8820
6. Curado M, Edwards B, Shin H, Storm H, Ferlay J, Heanue M, Boyle P (2008) Cancer incidence in five continents. International Agency for Research on Cancer
7. C Allemani M Sant R De Angelis R Marcos-Gragera JW Coebergh 2006 Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups Cancer 107 352 360 16770772 10.1002/cncr.21995 (Pubitemid 44036565)
8. KW Jung S Park HJ Kong YJ Won YK Boo HR Shin EC Park JS Lee 2010 Cancer statistics in Korea: incidence, mortality and survival in 2006-2007 J Korean Med Sci 25 1113 1121 20676319 10.3346/jkms.2010.25.8.1113
9. H Mani ES Jaffe 2009 Hodgkin lymphoma: an update on its biology with new insights into classification Clin Lymphoma Myeloma 9 206 216 19525189 10.3816/CLM.2009.n.042
10. JD Carreon LM Morton SS Devesa CA Clarke SL Gomez SL Glaser LC Sakoda MS Linet SS Wang 2008 Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996-2004 Cancer Causes Control 19 1171 1181 18543071 10.1007/s10552-008-9184-z
11. SJ Wu CY Chen IJ Su JL Tang WC Chou BS Ko SY Huang M Yao W Tsay YC Chen CH Wang HF Tien 2008 Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan J Formos Med Assoc 107 4 12 18218572 10.1016/S0929-6646(08)60002-9 (Pubitemid 351279874)
12. R Aoki K Karube Y Sugita Y Nomura K Shimizu Y Kimura K Hashikawa N Suefuji M Kikuchi K Ohshima 2008 Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006 Pathol Int 58 174 182 18251781 10.1111/j.1440-1827.2007.02207.x (Pubitemid 351190172)
13. WL Chen WC Tsai TY Chao LF Sheu JM Chou WY Kao YC Chen CL Ho 2010 The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan Ann Hematol 89 553 562 20012434 10.1007/s00277-009-0870-z
14. LM Morton SS Wang SS Devesa P Hartge DD Weisenburger MS Linet 2006 Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 Blood 107 265 276 16150940 10.1182/blood-2005-06-2508 1:CAS:528: DC%2BD28XhsVGlsg%3D%3D (Pubitemid 43053551)
15. SO Yoon C Suh DH Lee HS Chi CJ Park SS Jang HR Shin BH Park J Huh 2010 Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification Am J Hematol 85 760 764 20806229 10.1002/ajh.21824
16. B MacMahon 1966 Epidemiology of Hodgkin's disease Cancer Res 26 1189 1201 5329907 1:STN:280:DyaF287nt1yitg%3D%3D
17. B Schnitzer 2009 Hodgkin lymphoma Hematol Oncol Clin North Am 23 747 768 19577168 10.1016/j.hoc.2009.04.013
18. E Duhmke J Franklin M Pfreundschuh S Sehlen N Willich U Ruhl RP Muller P Lukas A Atzinger U Paulus B Lathan U Ruffer M Sieber J Wolf A Engert A Georgii S Staar R Herrmann M Beykirch H Kirchner A Emminger R Greil E Fritsch P Koch A Drochtert O Brosteanu D Hasenclever M Loeffler V Diehl 2001 Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone J Clin Oncol 19 2905 2914 11387364 1:STN:280: DC%2BD3MzhsVajtw%3D%3D (Pubitemid 32538201)
19. A Engert A Plutschow H Eich A Lohri B Dorken P Borchmann B Berger R Greil K Willborn M Wilhelm 2010 Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma N Engl J Med 363 640 652 20818855 10.1056/NEJMoa1000067 1:CAS:528:DC%2BC3cXhtVamtrrJ
20. C Ferme H Eghbali JH Meerwaldt C Rieux J Bosq F Berger T Girinsky P Brice MB van't Veer JA Walewski P Lederlin U Tirelli P Carde E Van den Neste E Gyan M Monconduit M Divine JM Raemaekers G Salles EM Noordijk GJ Creemers J Gabarre A Hagenbeek O Reman M Blanc J Thomas B Vie JC Kluin-Nelemans F Viseu JW Baars P Poortmans PJ Lugtenburg C Carrie J Jaubert M Henry-Amar 2007 Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease N Engl J Med 357 1916 1927 17989384 10.1056/NEJMoa064601 1:CAS:528:DC%2BD2sXht1ymtbnI (Pubitemid 350074687)
21. A Engert A Plutschow HT Eich A Lohri B Dorken P Borchmann B Berger R Greil KC Willborn M Wilhelm J Debus MJ Eble M Sokler A Ho A Rank A Ganser L Trumper C Bokemeyer H Kirchner J Schubert Z Kral M Fuchs HK Muller-Hermelink RP Muller V Diehl 2010 Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma N Engl J Med 363 640 652 20818855 10.1056/NEJMoa1000067 1:CAS:528:DC%2BC3cXhtVamtrrJ
22. GP Canellos JS Abramson DC Fisher AS LaCasce 2010 Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy J Clin Oncol 28 1611 1615 20159818 10.1200/JCO.2009.25.3260
23. DA Macdonald JM Connors 2007 New strategies for the treatment of early stages of Hodgkin's lymphoma Hematol Oncol Clin North Am 21 871 880 17908625 10.1016/j.hoc.2007.06.014 (Pubitemid 47487489)
24. DJ Straus CS Portlock J Qin J Myers AD Zelenetz C Moskowitz A Noy A Goy J Yahalom 2004 Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease Blood 104 3483 3489 15315964 10.1182/blood-2004-04-1311 1:CAS:528:DC%2BD2cXhtVGltLfJ (Pubitemid 39564416)
25. C Herbst FA Rehan C Brillant J Bohlius N Skoetz H Schulz I Monsef L Specht A Engert 2010 Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review Haematologica 95 494 500 19951972 10.3324/haematol.2009.015644 1:CAS:528:DC%2BC3cXht12msLrE
26. JM Connors P Klimo G Adams BF Burns I Cooper RM Meyer SE O'Reilly J Pater I Quirt A Sadura C Shustik J Skillings S Sutcliffe S Verma S Yoshida B Zee 1997 Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group J Clin Oncol 15 1638 1645 9193364 1:CAS:528:DyaK2sXivVehsLs%3D (Pubitemid 27167404)
27. JH Glick ML Young D Harrington RL Schilsky T Beck R Neiman RI Fisher BA Peterson MM Oken 1998 MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial J Clin Oncol 16 19 26 9440718 1:CAS:528:DyaK1cXmtlertA%3D%3D (Pubitemid 28041574)
28. S Viviani G Bonadonna A Santoro V Bonfante M Zanini L Devizzi F Soncini P Valagussa 1996 Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results J Clin Oncol 14 1421 1430 8622055 1:CAS:528:DyaK28XjtFKis7Y%3D (Pubitemid 26134197)
29. V Diehl K Behringer 2006 Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma? Cancer Invest 24 461 465 16777701 10.1080/07357900600705789 1:STN:280:DC%2BD28zmtlWrtw%3D%3D (Pubitemid 43932691)
30. M Henry-Amar S Friedman M Hayat R Somers JH Meerwaldt P Carde JM Burgers J Thomas M Monconduit EM Noordijk, et al. 1991 Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group Ann Intern Med 114 361 365 1992877 1:STN:280:DyaK3M7islyltg%3D%3D
31. TA Lister D Crowther SB Sutcliffe E Glatstein GP Canellos RC Young SA Rosenberg CA Coltman M Tubiana 1989 Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting J Clin Oncol 7 1630 1636 2809679 1:STN:280:DyaK3c%2FjvFCnsA%3D%3D (Pubitemid 19272832)
32. P Mauch R Goodman S Hellman 1978 The significance of mediastinal involvement in early stage Hodgkin's disease Cancer 42 1039 1045 698907 10.1002/1097-0142(197809)42:3<1039::AID-CNCR2820420302>3.0.CO;2-R 1:STN:280:DyaE1M%2Fit1OmsA%3D%3D (Pubitemid 9054556)
33. M Tubiana M Henry-Amar M Hayat M Burgers M Qasim R Somers W Sizoo E Van der Schueren 1984 Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease Cancer 54 885 894 6378359 10.1002/1097-0142(19840901)54:5<885::AID-CNCR2820540522>3.0.CO;2-B 1:STN:280:DyaL2c3lvV2gtA%3D%3D (Pubitemid 14058446)
34. D Hasenclever V Diehl 1998 A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease N Engl J Med 339 1506 1514 9819449 10.1056/NEJM199811193392104 1:STN:280:DyaK1M%2FisFenuw%3D%3D (Pubitemid 28543499)
35. T Zander S Wiedenmann J Wolf 2002 Prognostic factors in Hodgkin's lymphoma Ann Oncol 13 Suppl 1 67 74 12078906 (Pubitemid 34567404)
36. L Nogova T Reineke HT Eich A Josting HK Muller-Hermelink K Wingbermuhle C Brillant A Gossmann J Oertel MV Bollen RP Muller V Diehl A Engert 2005 Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG) Ann Oncol 16 1683 1687 16093276 10.1093/annonc/mdi323 1:STN:280:DC%2BD2MvpvFKhsw%3D%3D (Pubitemid 41510144)
37. A Wirth K Yuen M Barton D Roos K Gogna G Pratt C Macleod S Bydder G Morgan D Christie 2005 Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group Cancer 104 1221 1229 16094666 10.1002/cncr.21303 (Pubitemid 41278957)
38. LS Maeda RH Advani 2009 The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma Curr Opin Oncol 21 397 400 19606035 10.1097/CCO.0b013e32832f3ca3 1:CAS:528:DC%2BD1MXptl2itb4%3D
39. AI Lee AS LaCasce 2009 Nodular lymphocyte predominant Hodgkin lymphoma Oncologist 14 739 751 19605845 10.1634/theoncologist.2009-0099
40. I Biasoli A Stamatoullas V Meignin A Delmer O Reman F Morschhauser B Coiffier A Bosly M Divine P Brice 2010 Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group Cancer 116 631 639 20029973 10.1002/cncr.24819
41. C Jackson B Sirohi D Cunningham A Horwich K Thomas A Wotherspoon 2010 Lymphocyte-predominant Hodgkin lymphoma-clinical features and treatment outcomes from a 30-year experience Ann Oncol 21 2061 2068 20332141 10.1093/annonc/mdq063 1:STN:280:DC%2BC3cfktFartw%3D%3D
42. L Nogova T Reineke C Brillant M Sieniawski T Rudiger A Josting H Bredenfeld R Skripnitchenko RP Muller HK Muller-Hermelink V Diehl A Engert 2008 Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group J Clin Oncol 26 434 439 18086799 10.1200/JCO.2007.11.8869 (Pubitemid 351171696)